Spencer Feldman

Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in locally advanced hepatocellular carcinoma.

Chemotherapy regimen shows potential to improve survival and reduce need for surgery in patients with muscle-invasive bladder cancer.

Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with recurrent H3 K27M-mutant diffuse glioma.

In patients with triple-negative breast cancer, ctDNA was most commonly identified within six months after treatment, reflecting the disease’s typical pattern of early recurrence.

A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated CLL, an expert explained.

In certain patients with ESR1-mutant breast cancer, time to next treatment was slightly higher with Orserdu versus PFS in a phase 3 trial.

Maggie Bushway reflected on her memoir “Pearls: A Memoir on Childhood Cancer and Hope,” and her journey of healing and resilience after brain cancer.

MRIs were able to predict organ preservation and survival with the “watch-and-wait” approach in patients with rectal cancer.

Combination therapy of Lenvima with Ipex and Vepesid misses end goal in children with osteosarcoma, but further research is needed.

Partial nephrectomy showed similar overall and cancer-specific survival rates to radiofrequency ablation in patients with cT1a RCC.

The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed or refractory multiple myeloma.

Aerobic exercise improved self-reported cognitive function in women undergoing chemotherapy for breast cancer but had no effect on objective cognitive function.

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.

An Itovebi regimen demonstrated significantly longer progression-free survival compared with placebo in some with metastatic breast cancer.

An expert highlighted unmet needs in treating T-cell acute lymphoblastic leukemia and where research may focus in the future.

Adjuvant Opdivo showed a significant improvement in overall survival and disease-free survival for patients with high-risk muscle-invasive urothelial cancer after radical resection.

Initial Keytruda showed consistent antitumor activity and safety in patients with advanced bladder cancer ineligible for platinum-based chemotherapy.

New treatments for acute lymphoblastic leukemia may lead to fewer side effects than chemotherapy, as they target cancer cells more precisely, an expert said.

Treatment with Columvi showed a manageable safety profile in heavily pre-treated patients with relapsed or refractory mantle cell lymphoma.

The advantages and disadvantages of CAR-T cell therapy should be carefully thought about for patients with melanoma.

An expert told CURE that Trodelvy's side effects, such as neutropenia and fatigue, can often be managed through dose adjustments.

Ponsegromab helped patients with cachexia and elevated GDF-15 levels gain weight, increase activity and improve cachexia symptoms, with manageable safety.

The combination of Bavencio and gemcitabine showed promising efficacy and safety in certain patients with advanced leiomyosarcoma.

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and endocrinopathies.

Induction chemotherapy shows significant improvements for survival in patients with locally advanced cervical cancer.

Chemotherapy for three months demonstrates lower side effects, suggesting its use as standard care compared with six months.

Perioperative chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC) shows promising long-term benefits with minimal side effects.

Patients with resected stage 3 or 4 melanoma treated with immune-oncology agents demonstrated significantly higher cure rates compared to those treated with placebo.

Treatment containing Recentin demonstrated clinical benefits, but it proves worse than the current standard care treatment.